Verastem released extended RAMP 201 results in recurrent low-grade serous ovarian cancer, adding more than two years of median follow-up for avutometinib plus defactinib. The data were published in Gynecologic Oncology ahead of further updates at IGCSociety2026.
published
Verastem released extended RAMP 201 results in recurrent low-grade serous ovarian cancer, adding more than two years of median follow-up for avutometinib plus defactinib. The data were published in Gynecologic Oncology ahead of further updates at IGCSociety202
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.